COMPANY OF THE YEAR

Why Walmart is Yahoo Finance's 2024 winner

NasdaqGM - Nasdaq Real Time Price USD

Tectonic Therapeutic, Inc. (TECX)

45.58

+0.25

(+0.55%)

As of 1:54:15 PM EST. Market Open.

Tectonic Therapeutic to Host KOL Event on the Unmet Need in Group 2 PH-HFpEF and TX45 as a Potential Treatment on Thursday, December 12, 2024

WATERTOWN, Mass., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ: TECX) (“Tectonic”) a clinical stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-protein coupled receptors (“GPCRs”), today announced it will host a virtual key opinion leader (KOL) event on Thursday, December 12, 2024 from 4:00 PM to 6:00 PM ET. To register, click here. Key opinion leaders will include John R. Teerlink,

GlobeNewswire 12 days ago

TECX
+0.55%
Tectonic Therapeutic To Present on December 3rd, 2024 at the Piper Sandler Healthcare Conference

WATERTOWN, Mass., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ: TECX) (Tectonic), a clinical stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-protein coupled receptors (GPCRs), today announced that Alise Reicin, MD, President and Chief Executive Officer, will present at the Piper Sandler 36th Annual Healthcare Conference being held in New York on December 3-5, 2024. Piper Sandler 36

GlobeNewswire 19 days ago

TECX
+0.55%
Tectonic Therapeutic Inc. Reports Q3 2024 Results

Tectonic Therapeutic Inc ( (TECX) ) has released its Q3 earnings. Here is a breakdown of the information Tectonic Therapeutic Inc presented to its investors. Tectonic Therapeutic Inc., based in Watertown, Massachusetts, is a clinical-stage biotechnology company specializing in the development of therapeutic proteins and antibodies targeting G-protein coupled receptors (GPCRs) to address unmet medical needs. Tectonic recently announced its third-quarter 2024 financial results, highlighting signif

TipRanks last month

TECX
+0.55%
Tectonic Therapeutic Announces Positive Phase 1a Results in AHA 2024 Presentation for TX45, a Long-acting, Fc-Relaxin Fusion Protein

Phase 1a results support further development of TX000045 (“TX45”) for Group 2 Pulmonary Hypertension in HFpEF (“PH-HFpEF”), based on favorable pharmacokinetic profile and impact on renal plasma flow (“RPF”)TX45 showed a favorable safety profile, with no observed injection site reactions, immunogenicity, or detection of anti-drug antibodiesRPF-based exposure-response model enabled APEX Phase 2 dose selectionUpcoming topline results from the ongoing TX45 clinical program includes Phase 1b hemodyna

GlobeNewswire last month

TECX
+0.55%
Tectonic Therapeutic Announces Third Quarter 2024 Financial Results and Recent Business Highlights

Patient enrollment in the Phase 1b hemodynamic trial remains ahead of expectation, with topline results now expected in late Q1’2025 or early Q2’2025First subject dosed with TX000045 (“TX45”) in APEX Phase 2 clinical trial in early October, with topline results expected in 2026Development Candidate TX002100 (“TX2100”) selected for second program targeting patients with Hereditary Hemorrhagic Telangiectasia (HHT)Cash and cash equivalents were $159.1 million as of September 30, 2024, expected to p

GlobeNewswire last month

TECX
+0.55%
Tectonic Therapeutic Independent Director Acquires 7.0% More Stock

Tectonic Therapeutic, Inc. ( NASDAQ:TECX ) shareholders (or potential shareholders) will be happy to see that the...

Simply Wall St. last month

TECX
+0.55%
Tectonic Therapeutic to Present Phase 1a Data at AHA 2024

American Heart Association (AHA) poster to be presented on November 16, 2024WATERTOWN, Mass., Oct. 22, 2024 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ: TECX) (Tectonic), a clinical stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-protein coupled receptors (“GPCRs”), today announced that it will present a poster at AHA 2024 highlighting Phase 1a data for its lead asset TX000045 (“TX45”), a long-

GlobeNewswire last month

TECX
+0.55%
Tectonic Therapeutic (NASDAQ:TECX) Is In A Good Position To Deliver On Growth Plans

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...

Simply Wall St. 2 months ago

TECX
+0.55%
Tectonic Therapeutic Announces Favorable Phase 1a Safety, Tolerability and PK/PD Results for Lead Program TX45

TX45 was well-tolerated with no observed immunogenicity, and demonstrated a favorable PK/PD relationship which was used to identify doses for the Phase 2 clinical trial Results to be presented at the American Heart Association (AHA) Scientific Sessions in November 2024 Phase 1b single dose hemodynamic proof-of-concept clinical trial in Group 2 Pulmonary Hypertension in Heart Failure with Preserved Ejection Fraction (PH-HFpEF) escalated to the highest dose of TX45 (3 mg/kg) based on favorable tol

GlobeNewswire 2 months ago

TECX
+0.55%
Tectonic Therapeutic to Participate in September Investor Conferences

WATERTOWN, Mass., Aug. 20, 2024 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ: TECX) (Tectonic), a clinical stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-protein coupled receptors (GPCRs), today announced that company management will present at the 2024 Wells Fargo Healthcare Conference being held in Boston on September 4-6, 2024 and participate in the Morgan Stanley 22nd Annual Global Healthca

GlobeNewswire 3 months ago

TECX
+0.55%
Tectonic Therapeutic Announces Second Quarter 2024 Financial Results and Recent Business Highlights

TX45 advances into Phase 2 clinical trial for patients with Group 2 PH-HFpEF with first site activated and screening open in August 2024Received U.S. Investigational New Drug (IND) clearance for lead program, TX45 in July 2024Completed reverse merger with AVROBIO in June 2024, including concurrent private placement of $130.7 millionCash and cash equivalents were $185.1 million as of June 30, 2024, prior to the payment of accrued transaction and related expenses of approximately $14.4 million, ar

GlobeNewswire 3 months ago

TECX
+0.55%
Tectonic Therapeutic Announces US IND Clearance for Lead Program, TX45

TX45 is an Fc-relaxin fusion protein being evaluated in patients with Group 2 Pulmonary Hypertension (PH) due to Heart Failure with Preserved Ejection Fraction (HFpEF), a serious condition estimated to affect over 600,000 people in the U.S. alone, currently with no approved therapiesPlanned initiation of global, 24-week Phase 2 clinical trial to evaluate TX45 administered subcutaneously in subjects with Group 2 PH due to HFpEF (PH-HFpEF) in the third quarter of 2024, with topline trial results e

GlobeNewswire 4 months ago

TECX
+0.55%
Tectonic Therapeutic Announces Closing of Merger with AVROBIO as well as Concurrent Private Placement of $130.7 Million

WATERTOWN, Mass., June 20, 2024--Tectonic Therapeutic Announces Closing of Merger with AVROBIO as well as Concurrent Private Placement of $130.7 Million

Business Wire 5 months ago

TECX
+0.55%

Performance Overview

Return	TECX	S&P 500
YTD	+179.29%	+27.54%
1-Year	+179.29%	+28.91%
3-Year	+9.15%	+29.16%